Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Akkermansia muciniphila

Next-Generation Mucin-Degrading Probiotic

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

3 human trials, about 60 studies, ~1,000 participants. The written rationale for this grade is still being prepared.

FDA
Supplement (Pendulum)
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Across the human trials to date, both live and pasteurized Akkermansia were reported safe and well tolerated with no treatment-related serious adverse events, and EFSA judged the pasteurized novel food safe at capped doses for adults. Important caveats: the live anaerobe is technically demanding to keep viable (it dies on oxygen exposure), human intervention data remain limited and modest in effect, and abundance is context-dependent rather than always beneficial. It has not been established as safe or effective in pregnancy, in children below the ages covered by regulators, or in people who are immunocompromised or have serious illness. Anyone considering it for diabetes, obesity, weight management, or alongside cancer treatment should first consult a qualified healthcare provider, since it is not a substitute for prescribed therapy.

Akkermansia muciniphila is a bacterium of the gut mucus layer that feeds on mucin and has become the flagship next-generation probiotic. High abundance is associated with metabolic health, leanness, better insulin sensitivity, and response to cancer immunotherapy, and the mechanistic and mouse data are unusually strong. The human clinical case is narrower: three small randomized trials, mostly industry-linked, show real but modest metabolic and weight-maintenance signals, with one trial finding benefit only in people who started with low Akkermansia. Both a pasteurized (non-living) form, cleared as an EU novel food, and a live form, sold in the US as a supplement, are now commercial. It is among the most promising single organisms in the field and also a textbook correlation-versus-causation question.

A gut-lining bacterium tied to metabolic health, leanness, and immunotherapy response.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Metabolic syndrome, insulin resistance, and glucose management (associated with, strongest human evidence)
  • Weight-loss maintenance after dieting (2026 pasteurized-MucT RCT signal)
  • Gut mucus-barrier support and gut-lining integrity
  • Type 2 diabetes support, notably in people with low baseline Akkermansia (Zhang 2024)
  • Cancer immunotherapy response research (observational and mouse-model, not a human intervention indication)

What people get wrong

  • Often saidAkkermansia is a miracle weight-loss bacterium

    ActuallyThe metabolic and leanness associations are strong and there are now three small randomized trials with real signals, but the effects on weight are modest and inconsistent. In Depommier 2019 the weight change was not statistically significant (P=0.091); in Zhang 2024 weight and HbA1c benefits appeared only in people who started with low Akkermansia; the 2026 maintenance trial showed a roughly 2 kg advantage in regain, which independent experts called a proof of concept, not a substitute for GLP-1 drugs or diet.

  • Often saidThe pasteurized (dead) version cannot work because the bacteria are not alive

    ActuallyCounterintuitively, the non-living pasteurized form has carried much of the human evidence. Depommier 2019 reported the pasteurized form outperformed the live one on metabolic markers, and both the 2026 maintenance RCT and the EU novel-food authorization are for pasteurized MucT. A specific outer-membrane protein, Amuc_1100, is associated with much of the effect and survives pasteurization, which is why researchers describe it as a postbiotic.

  • Often saidMore Akkermansia is always better

    ActuallyAbundance is not linearly beneficial. In lung cancer, moderately elevated intestinal Akkermansia predicted the best immunotherapy response while very high levels (above roughly 4.8 percent), especially after antibiotics, associated with worse outcomes. Elevated Akkermansia has also been observed in Parkinson's disease, multiple sclerosis, and Alzheimer's, and over-colonization can thin the protective mucus barrier, so it behaves as a context-dependent organism, not a dose-more-is-better supplement.

  • Often saidAkkermansia supplements are FDA-approved to treat diabetes or obesity

    ActuallyIn the United States, live Akkermansia products such as Pendulum's are sold as dietary supplements, not FDA-approved drugs, so lawful claims are structure-function only. In the EU, pasteurized Akkermansia muciniphila MucT is authorized as a novel food ingredient, which is a food-safety clearance, not a medicine approval or a proof of efficacy for any disease.

Who profits, and who pushes back

  • Prof Kieran Tuohy

    Pushes backProfessor of Energy Metabolism and the Microbiome, University of Leeds (independent expert, Science Media Centre reaction, 2026)

    Tuohy notes that despite the positive 2026 maintenance trial, 'further mechanistic studies in humans are needed to uncover how this all works,' and that the study duration was short and timing of measurements can determine whether changes are seen.

  • Dr Jose Pablo Miramontes Gonzalez

    Pushes backConsultant in Internal Medicine, Rio Hortega Hospital, Valladolid (independent expert, Science Media Centre reaction, 2026)

    He cautions that 'it is a small, short-term study conducted in a highly selected population,' that the effect is 'modest' and does not make Akkermansia an alternative to incretin (GLP-1) agonists, and that it should be read 'as proof of concept, not as definitive evidence to change clinical practice.'

  • Dr Francisco Jesus Gomez Delgado

    Pushes backHead of Internal Medicine and coordinator of the Vascular Risk Unit, Jaen University Hospital (independent expert, Science Media Centre reaction, 2026)

    He states the trial's 'sample size is small, the follow-up period is short, and the demonstrated effect on body weight is limited,' and that it lacks active comparators, framing it as proof of concept rather than definitive evidence.

  • Dr. Patrice Cani

    Promotes itUCLouvain researcher

    Pioneered Akkermansia metabolic research; showed pasteurized Akkermansia improved markers in a human pilot. Academic.

  • Pendulum Therapeutics

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itCommercial brand

    First to commercialize a live Akkermansia product; genuine science, direct commercial interest.

Where the research comes from

Share of published research by country of origin.
PlaceShare of published research
USA38%
Other32%
Belgium30%

Research published from: Belgium, USA, Global.

How we got here

Akkermansia muciniphila was first isolated in 2004 by Muriel Derrien during her PhD with Willem de Vos at Wageningen University in the Netherlands, from healthy human feces, and named for Dutch microbial ecologist Antoon Akkermans. Because the organism lives across human populations worldwide as a normal member of the gut mucus layer, its story is a shared human-microbiome one rather than a regional discovery. Through the 2010s, Patrice Cani's group in Belgium linked this single mucus-dwelling organism to metabolic health: low in obesity and diabetes, high in leanness. A pilot using pasteurized Akkermansia reported improved insulin sensitivity, and, unusually, the non-living pasteurized form outperformed the live one. Cani and de Vos co-founded A-Mansia (The Akkermansia Company) and hold patents on its use; Pendulum, separately, brought the first live Akkermansia to US consumers. Danone acquired The Akkermansia Company in 2025.

  1. 2004Akkermansia muciniphila first isolated by Derrien and de Vos at Wageningen, from healthy human stool
  2. 2013Cani lab (PNAS) shows Akkermansia reverses metabolic disorders in obese mice, launching the metabolic-health hypothesis
  3. 2016A-Mansia (The Akkermansia Company) co-founded by Cani and de Vos around pasteurized-Akkermansia patents
  4. 2018Routy et al (Science) report low fecal Akkermansia in non-responders to anti-PD-1 cancer immunotherapy; oral Akkermansia restores response in mice
  5. 2019Depommier et al (Nature Medicine) publish the first human proof-of-concept RCT (n=40 enrolled/32 completed); pasteurized form improves insulin sensitivity
  6. 2021EFSA and the European Commission clear pasteurized Akkermansia muciniphila MucT as a novel food (max 5x10^10 cells/day for adults)
  7. 2022Pendulum introduces the first live Akkermansia product to the US market as a dietary supplement
  8. 2024Zhang et al (Cell Metabolism) RCT (n=58) finds live Akkermansia helps type 2 diabetes only in people with low baseline abundance
  9. 2025Danone acquires The Akkermansia Company; EFSA extends approved use to adolescents at capped doses
  10. 2026Mount/Canfora et al (Nature Medicine) RCT (n=90) meets primary endpoint for weight-loss maintenance with pasteurized MucT after a low-energy diet

At a glance

Habitat
Gut mucus layer
Associated with
Leanness, metabolic health
Brand
Pendulum (~$59.99/mo)
Challenge
Anaerobic, hard to formulate

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Akkermansia muciniphila. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources